Full Claim Scope Must Be Enabled To Avoid Invalidity
Client Alert | 1 min read | 02.05.08
In Sitrick v. Dreamworks, LLC, (No. 07-1174, February 1, 2008), a Federal Circuit panel affirms a district court’s judgment of invalidity for lack of enablement. The claims at issue are directed to integrating user generated audio or visual content into a pre-existing video game or movie by “selectively substitut[ing] user image data for predefined character image data so as to provide an audiovisual presentation that includes the [user provided] image integrated therein.” The accused product allows users to combine their own voice with pre-existing video images stored on a DVD.
Citing to Auto. Techs. Int’l, Inc. v. BMW of N. Am., Inc., 501 F.3d 1274 (Fed. Cir. 2007), the panel reasons that, because the asserted claims are broad enough to cover both movies and video games, the patent disclosure must enable both embodiments. According to the panel opinion, a “patentee who chooses broad claim language must make sure the broad claims are fully enabled.” The asserted claims are not deemed to be enabled in the context of movies because, unlike video games, movies do not rely on discrete address and control signals. In support of its conclusion, the Federal Circuit panel also notes the undisputed evidence showing that it is difficult, if not impossible, to isolate any one voice from the rest of the sounds in movie soundtracks.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
